Clinical Trials for Colorectal Cancer
GI008
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease. View details.
OrigAMI-3
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy. View details.
